Trial Profile
Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Carcinoma; Endometrial cancer; Leiomyosarcoma; Sarcoma; Uterine cancer
- Focus Therapeutic Use
- 04 Apr 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.
- 04 Apr 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2024.
- 07 Jun 2022 Results investigating if high-depth circulating cell free (cf)DNA sequencing can be used to assess MSI status and monitor ICI response in EC patients enrolled in a phase II trial presented at the 58th Annual Meeting of the American Society of Clinical Oncology